Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma

INTRODUCTION: Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a platinum drug remains the only licensed standard of care. As the median survival for patients with mesothelioma is 12.1 months, surgery is an important consideration to improve survival and/or quality...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMJ Open
Egile Nagusiak: Lim, Eric, Darlison, Liz, Edwards, John, Elliott, Daisy, Fennell, D A, Popat, Sanjay, Rintoul, Robert C, Waller, David, Ali, Clinton, Bille, Andrea, Fuller, Liz, Ionescu, Andreea, Keni, Manjusha, Kirk, Alan, Koh, Pek, Lau, Kelvin, Mansy, Talal, Maskell, Nick A, Milton, Richard, Muthukumar, Dakshinamoorthy, Pope, Tony, Roy, Amy, Shah, Riyaz, Shamash, Jonathan, Tasigiannopoulos, Zacharias, Taylor, Paul, Treece, Sarah, Ashton, Kate, Harris, Rosie, Joyce, Katherine, Warnes, Barbara, Mills, Nicola, Stokes, Elizabeth A, Rogers, Chris
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Oncology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7467531/
https://ncbi.nlm.nih.gov/pubmed/32873681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-038892
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak